The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study
| Autor: | Edoardo Francini, Virginia Livellara, Steven R. Alberts, Guido Francini, Guido Pesola, Eric G. Wolfe, Fang-Shu Ou, Joleen M. Hubbard, Elena Colombo, Sara Cherri, Roberto Petrioli, Luciana Messuti, Stefano Lazzi, Salvatora Tindara Miano, Harry H. Yoon, Andrea Giovanni Multari, Serena Bazzurri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Colorectal cancer Adjuvant chemotherapy CD3 chemical and pharmacologic phenomena lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Prognostic marker Internal medicine medicine Adjuvant therapy Risk factor Original Research biology Tumor-infiltrating lymphocytes business.industry T-cells Fluoropyrimidines hemic and immune systems lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Immunohistochemistry business Cohort study Post-surgery treatment |
| Zdroj: | Translational Oncology Translational Oncology, Vol 14, Iss 2, Pp 100973-(2021) |
| ISSN: | 1936-5233 |
| Popis: | Highlights • Low CD3+ TILs rate was associated with shorter OS in those with stage II colon cancer who did not receive adjuvant therapy. • CD3+ TILs rate was not prognostic for patients with stage II colon cancer who had adjuvant therapy. • Low CD3+ TILs rate may be an additional risk factor for stage II colon cancer patients who did not have adjuvant therapy yet. Background High tumor infiltrating lymphocytes (TILs) density was previously shown to be associated with favorable prognosis for patients with colon cancer (CC). However, the impact of TILs on overall survival (OS) of stage II CC patients who received adjuvant chemotherapy (ADJ) or not (no-ADJ) is unknown. We assessed the prognostic value of CD3+ TILs in stage II CC patients according to whether they had ADJ or not. Methods Patients treated with curative surgery for stage II CC (2002–2013) were selected from the Santa Maria alle Scotte Hospital registry. TILs at the invasive front, center of tumor, and stroma were determined by immunohistochemistry and manually quantified as the rate of TILs/total tissue areas. High TILs (H-TILs) was defined as >20%. Patients were categorized as high or low TILs (L-TILs) and ADJ or no-ADJ. Results Of the 678 patients included, 137 (20%) received ADJ and 541 (80%) did not. The distribution of the 4 groups were: 16% (L-TIL/ADJ), 64% (L-TIL/no-ADJ), 5% (H-TIL/ADJ), 15% (H-TIL/no-ADJ). Compared to H-TILs/no-ADJ, ADJ patients showed a significantly increased OS (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|